TGFB1 and neoplasm: Collectively, exosome nanovaccines that block TGFβ signaling not only dismantle immune suppression in the TME but also reprogram it into an immunostimulatory niche, facilitating robust anti-tumor immune responses and enhancing the effectiveness of immunotherapy.